CREBBP and glioma: Taken together, our results demonstrate that inhibition of Wnt/CBP/β-catenin signaling can induce glioma cell differentiation in vitro and in vivo, modify the TME, and affect immune cell populations in the TME, shifting towards more effective dendritic cell presentation and a more effective T cell response, thereby potentially enhancing immunotherapeutic interventions in glioma patients.